bcl-2


Also found in: Medical, Acronyms, Wikipedia.

bcl-2

(biochemistry)
A family of proteins that operate in the effector phase of apoptosis and may either promote or inhibit apoptosis.
References in periodicals archive ?
The Bcl-2 family modulates cell apoptosis by either pro- or anti-apoptotic members.
Kaspaz aktivitesini engelleyen inhibitorler, Bcl-2 kontrol noktalarina mudahale eden molekuller, SMAC taklit eden molekuller, anti-saperon antisens ajanlarinin kullanimi, halihazirda klinik olarak degerlendirilen yaklasimlarin basinda gelmektedir (2).
The procaspase-3 protein contents, and Bcl-2 mRNA and protein contents were significantly decreased while caspase-3 protein contents, and Bax mRNA and protein contents were concomitantly increased in the concentration-dependent manner in FA groups (P 0.
MCF-7 cancer cell lines are characterized by resistance chemotherapeutic agents, [17,18] responsive estrogen receptors (ER+), overexpression of Bcl-2, [19,20] and with no expression of Caspase 3.
m] across the inner mitochondrial membrane, and the antiapoptotic protein Bcl-2 in the ER and outer mitochondrial membrane of irradiated cells.
Western blot analysis of cyclin D1, c-myc, and bcl-2 in the unclipped kidney from 2K1C rats treated or not with lisinopril was done.
18 It has recently been shown that Bcl-2 expression by mouse hepatocytes protects them from Fas-mediated apoptosis, suggesting the potential for alternative approaches to the prevention of hepatic failure due to viral hepatitis in man.
Bcl-2 activity upregulates in many types of cancer and correlates with cancer cell resistance to a wide spectrum of chemotherapy agents.
Methods: To study the effects of Pt-AZT on hepatocellular carcinoma and compare its effects with AZT in inhibition of telomerase and Bcl-2 gene expression, pathogen-free male Wistar rats (n=100) were used.
Canine transmissible venereal tumor: expression of MDR-1, and TP53 and BCL-2 family genes and its implications in biological and therapeutic behavior ***
Stone and his colleagues have discovered that in patients who become tamoxifen-resistant, a gene called BCL-2 is weakened to the extent it literally switches off--and this process is potentially detectable in the blood, providing a diagnostic marker.